Start here if you're new
what it is
CAMP4 tries to turn on healthy protein production for genetic diseases, and it brought in $4M of annual revenue.
how it gets paid
Last year CAMP4 made $4M in revenue (segment rows sum to that). Collaboration revenue was the main engine at $2.4M, or 60% of sales.
what just happened
CAMP4 posted $3M in latest-quarter revenue while EPS landed at -$1.78.
At a glance
n/a balance sheet
-$11.04 fy2024 eps est
~$4M FY revenue (segment table)
~$281M market cap
small cap
What they do
CAMP4 tries to turn on healthy protein production for genetic diseases, and it brought in $4M of annual revenue.
The RAP Platform® maps regRNAs, the RNA switches that control gene output, so the team can aim at the cause instead of the symptom. That matters because you are not betting on one pill; you are betting on a platform that can point at multiple gene targets. The contrast is brutal: $4M in 2024 revenue versus a $17.5M GSK upfront.
How they make money
$4M
annual revenue
collaboration revenue
$2.4M
upfront and milestone revenue
$1.0M
research revenue
$0.4M
other income
$0.2M
The products that matter
drug discovery engine
RAP Platform
~$4M FY revenue (table)
it is the core technology behind the company, but the whole disclosed top line is still only ~$4M against a ~$281M market cap—that is a science valuation, not a commercial one.
platform
lead pipeline candidate
SYNGAP1 program
preclinical stage
this is the lead internal program, and it still has no human trial data. if you own CAMP, this is one of the programs your capital is paying to advance.
pipeline
external funding stream
Collaboration agreements
$2.4M collaboration · largest line
collaboration is the biggest named line in the table. at ~$4M total revenue, it validates partner interest but does not fund a preclinical biotech on its own.
cash trickle
Key numbers
$281M
market value
The market is pricing a $281M company around a business that only made $4M in annual revenue.
$4M
annual revenue
This is the whole top line base from VL, so every extra dollar matters.
$3M
latest quarter
The latest quarter is still tiny, even after 296% vs. prior year growth.
$3M
long-term debt
Debt is small at $3M, or 1% of capital, so the balance sheet is not the main problem.
Financial health
n/a
strength
- balance sheet grade n/a
- long-term debt $3M (1% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for CAMP right now.
source: institutional data · return history unavailable
What just happened
missed estimates
CAMP4 posted $3M in latest-quarter revenue while EPS landed at -$1.78.
Revenue was up 296% vs. prior year, but the business still ran at a loss. That is the whole story in one line: more sales, still no profit.
$3M
rev (q)
-$1.78
eps (q)
+296%
rev vs. prior year (q)
the number that mattered
The $3M quarter matters because it is the only hard top-line number here, and it is still tiny next to a $281M valuation.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is the RAP platform and SYNGAP1 pipeline staying preclinical without producing human proof.
med
No clinical data yet
The lead program, including SYNGAP1, is still preclinical. That means no human efficacy data, no safety readout, and no proof that the platform works where it counts.
With ~$4M in trailing revenue on this page, the vast majority of the $281M market value depends on future data, not present operations.
med
Dilution is part of the business model
The company raised $30M in dec 2025 to extend runway into 2028. That's rational. It also tells you equity financing remains a core operating tool while losses and development spending continue.
If progress to the clinic slips while cash burn continues, existing shareholders can be asked to fund the gap again.
med
Thin operating base leaves no cushion
The page shows ~$4M annual revenue in the segment table and no product sales. However you slice it, the operating base is tiny relative to the cost structure.
A business this early has almost no commercial buffer. Bad data, delayed milestones, or weaker partner interest would hit sentiment quickly.
A company with ~$4M in revenue on this page, no product sales, and a preclinical pipeline is worth $281M only if the science keeps earning credibility.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
march 26, 2026 earnings update
For CAMP, earnings are really a balance-sheet update. Watch burn, runway commentary, and whether management says anything concrete about getting programs toward the clinic.
financing
whether the dec 2025 raise actually holds the runway into 2028
Management says the $30M raise extended cash into 2028. Every quarter from here is a test of that claim. If burn runs hotter than expected, dilution comes back to the front of the story.
pipeline
any step from preclinical work toward an IND
An Investigational New Drug filing would not prove the science works, but it would mark a real transition from platform promise to clinical execution.
revenue
whether collaboration revenue stays a trickle or becomes a signal
Watch whether collaboration and milestone lines grow off a ~$4M FY base. If they compound, partners may be validating the platform. If the total stays tiny, the market remains dependent on future trial data.
Analyst rankings
source: institutional data
Institutional activity
institutional ownership data for CAMP is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive